ID26334A - Morfolinol yang aktif secara farmasi - Google Patents
Morfolinol yang aktif secara farmasiInfo
- Publication number
- ID26334A ID26334A IDW20001597A ID20001597A ID26334A ID 26334 A ID26334 A ID 26334A ID W20001597 A IDW20001597 A ID W20001597A ID 20001597 A ID20001597 A ID 20001597A ID 26334 A ID26334 A ID 26334A
- Authority
- ID
- Indonesia
- Prior art keywords
- morpholinol
- activate
- pharmaceutical
- pharmaceutical activate
- activate morpholinol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801230.5A GB9801230D0 (en) | 1998-01-21 | 1998-01-21 | Pharmaceutically active morpholinol |
| US7218098P | 1998-01-22 | 1998-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID26334A true ID26334A (id) | 2000-12-14 |
Family
ID=26312986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDW20001597A ID26334A (id) | 1998-01-21 | 1999-01-20 | Morfolinol yang aktif secara farmasi |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6274579B1 (id) |
| EP (2) | EP1047428B1 (id) |
| JP (1) | JP2002501025A (id) |
| KR (1) | KR100568063B1 (id) |
| CN (2) | CN1203858C (id) |
| AP (1) | AP1229A (id) |
| AT (1) | ATE365042T1 (id) |
| AU (1) | AU755536B2 (id) |
| BR (1) | BR9907203A (id) |
| CA (1) | CA2318268A1 (id) |
| CY (1) | CY1106828T1 (id) |
| DE (1) | DE69936335T2 (id) |
| DK (1) | DK1047428T3 (id) |
| EA (1) | EA002410B1 (id) |
| EE (1) | EE04452B1 (id) |
| ES (1) | ES2288012T3 (id) |
| HR (2) | HRP20000494B1 (id) |
| HU (1) | HUP0100900A3 (id) |
| ID (1) | ID26334A (id) |
| IL (2) | IL161942A0 (id) |
| IS (1) | IS2494B (id) |
| NO (2) | NO326878B1 (id) |
| NZ (3) | NZ529316A (id) |
| PL (1) | PL193622B1 (id) |
| PT (1) | PT1047428E (id) |
| SG (1) | SG115489A1 (id) |
| SK (1) | SK10912000A3 (id) |
| TR (1) | TR200002126T2 (id) |
| WO (1) | WO1999037305A1 (id) |
| YU (1) | YU67102A (id) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098206B2 (en) | 1998-01-21 | 2006-08-29 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6998400B2 (en) * | 1998-01-22 | 2006-02-14 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| CA2318920A1 (en) | 1998-01-29 | 1999-08-05 | James W. Young | Pharmaceutical uses of optically pure (-)-bupropion |
| US6458374B1 (en) | 1998-01-29 | 2002-10-01 | Sepracor, Inc. | Methods and compositions for treating chronic disorders using optically pure (+)-bupropion |
| US6734213B2 (en) | 1999-01-20 | 2004-05-11 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6855820B2 (en) | 1999-01-20 | 2005-02-15 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| JP2003511410A (ja) * | 1999-10-13 | 2003-03-25 | グラクソ グループ リミテッド | 肥満症の治療のためのモルホリノール誘導体 |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| CA2365428C (en) * | 2000-12-21 | 2008-10-21 | Brasscorp Limited | Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing |
| US6979104B2 (en) | 2001-12-31 | 2005-12-27 | R.J. Doran & Co. LTD | LED inspection lamp |
| EP2301537A1 (en) * | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| US7384941B2 (en) * | 2002-08-23 | 2008-06-10 | Eli Lilly And Company | 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| CN1784221B (zh) * | 2003-04-29 | 2010-07-07 | 奥雷西根治疗公司 | 影响体重减轻的组合物 |
| WO2005042503A1 (en) * | 2003-10-27 | 2005-05-12 | Smithkline Beecham Corporation | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof |
| GB0325055D0 (en) * | 2003-10-27 | 2003-12-03 | Smithkline Beecham Corp | New process |
| GB0326148D0 (en) * | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| GB0327619D0 (en) * | 2003-11-27 | 2003-12-31 | Smithkline Beecham Corp | New use |
| EP1734955A2 (en) | 2004-01-13 | 2006-12-27 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| RU2006139930A (ru) * | 2004-05-03 | 2008-06-10 | Дюк Юниверсити (Сша/Сша) (Us) | Составы для содействия снижению веса |
| FI117283B (fi) | 2005-02-04 | 2006-08-31 | Kone Corp | Hissijärjestelmä |
| MX337422B (es) | 2005-11-22 | 2016-03-04 | Orexigen Therapeutics Inc | Composiciones y metodos para incrementar la sencibilidad a la insulina. |
| WO2007079470A2 (en) | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| TWI609702B (zh) | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
| KR20140088619A (ko) | 2006-11-09 | 2014-07-10 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
| JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
| CA2758774C (en) | 2009-04-15 | 2015-02-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| KR101841442B1 (ko) | 2010-01-11 | 2018-03-23 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
| AU2011255276B2 (en) | 2010-05-21 | 2016-09-22 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| ES2546492T3 (es) | 2010-05-21 | 2015-09-24 | Research Triangle Institute | Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia |
| US9510405B2 (en) | 2011-06-30 | 2016-11-29 | Schneider Electric Industries Sas | Dual power SMPS for a modular lighting system |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| CA2875056C (en) | 2012-06-06 | 2024-03-26 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| RU2763728C1 (ru) * | 2021-06-17 | 2021-12-30 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US170430A (en) * | 1875-11-30 | Improvement in furnaces for heating steel in tempering | ||
| GB8417170D0 (en) * | 1984-07-05 | 1984-08-08 | Wellcome Found | Heterocyclic pharmaceutical compounds |
| GB9108629D0 (en) | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
-
1999
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en active IP Right Grant
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active IP Right Cessation
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
-
2000
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-21 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
-
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
-
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
-
2005
- 2005-12-29 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
-
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
-
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID26334A (id) | Morfolinol yang aktif secara farmasi | |
| ID28110A (id) | Surfaktan alkilbenzenasulfonat yang disempurnakan | |
| ID27841A (id) | Turunan-turunan biaril terapeutik | |
| IS5425A (is) | Læknislyf | |
| DE69924365D1 (de) | Massagegerät | |
| ID23299A (id) | Formulasi-formulasi farmasi | |
| DE69834019D1 (de) | Dose | |
| ID26330A (id) | Polipeptida-polipeptida yang bergantung vitamin k yang dimodifikasi | |
| ID27415A (id) | Komposisi farmaseutik | |
| ID22939A (id) | Formulasi-formulasi farmasi yang mengandung vorikonozal | |
| NO992692D0 (no) | Nefadozon doseringsform | |
| ID29262A (id) | Komposisi farmasi | |
| DK1466615T3 (da) | Farmaceutisk præparat | |
| DE69921571D1 (de) | Massagegerät | |
| DE69908262D1 (de) | Sprühbehälter | |
| ID23735A (id) | Tablet trovafloksasin mesilat | |
| ID27201A (id) | Komposisi farmasi | |
| NO994619D0 (no) | Farmasöytiske blandinger | |
| ID30032A (id) | Formulasi farmasi | |
| DK1051156T3 (da) | Farmaceutiske præparater | |
| FR2782671B3 (fr) | Livre | |
| DE59904743D1 (de) | Exzenteranordnung | |
| ID29823A (id) | Mengirimkan nomor yang diputar | |
| ID27593A (id) | Tetrahidronaftilidinil-karboksamida yang mempunyai aktivitas anti-konvulsan | |
| FR2759452B3 (fr) | Fontaines pyro-aquatiques |